Connect with us

Health

ASLM Partners Africa CDC on Diagnostic Agenda in Africa

Published

on

The African Society for Laboratory Medicine (ASLM) has partnered with the Africa Centres for Disease Control and Prevention to address existing barriers towards advancing the diagnostic agenda in Africa through the launching of the Africa Collaborative Initiative to Advance Diagnostics (AFCAD).

This strategic partnership was announced during a press conference held on Wednesday, December 12, 2018, at the Transcorp Hilton Hotel, Abuja, to increase access to quality diagnostics towards the achievement of universal health coverage in Africa.

Speaking at the conference, Dr. Yenew Kebede, the Head of Laboratory Division, Africa CDC, stated that Universal Health Coverage is a priority for African countries to attain inclusive and sustainable growth, noting that many diseases remain undiagnosed due to poor diagnostic capacity in most African countries.

He said: “The limited access to essential tests and slow introduction of innovative technologies result in insufficient disease case finding and hampers access to, and monitoring of, treatment. Barriers to diagnostics prevent the African continent from becoming free of epidemic-prone diseases and compromise the achievement of the health agenda of the African Union”.

Other partners on this initiative include: Institut de Recherche, de Surveillance Epidémiologique et de Formation (IRESSEF), World Health Organization Africa Regional Office (WHO-AFRO), Clinton Health Access Initiative (CHAI), African Field Epidemiology Network (AFENET) and UNITAID.

Mr Nqobile Ndlovu, the acting CEO, ASLM said: “This partnership is timely for this period, especially with this year’s conference and its relation to the theme: ‘Controlling the next pandemic: The role of The Laboratory’. ASLM is happy to partner with Africa CDC to launch this initiative in promotion of the diagnostic agenda in the African region through better coordinated and synergized efforts that align with the priorities of Ministries of Health”.

Over the last decade, significant investments have been made by national governments, NGOs, partners and donors to address the technical, health system and financial roots of diagnostic gaps in Africa.

However, there is still a lot more to be done, explained Prof. Alash’le Abimiku, Chairperson, ASLM Board of Directors. “This is why this collaborative effort is so important. When we had the Ebola crisis in Africa, one major challenge laboratory experts had was the time spent in getting the samples tested.  Sometimes, it took up to four weeks just for blood samples to get tested because they had to be taken to Germany.  But with this new initiative, regulations will be accelerated to facilitate timely and wider access to essential diagnostics”, she said.

The role of AFCAD will be to support efforts that will enable all Member States to achieve equitable access of up to 80 percent coverage to the essential package of healthcare, taking advantage of technological innovations delivered through optimized integrated laboratory networks. This is expected to support achievement of the Sustainable Development Goals as well as improved adherence to International Health Regulations (2015).

AFCAD will also support African health systems through early detection and prevention of antimicrobial resistance, reducing the barriers to early detection, prevention and management of non-communicable diseases such as cardiovascular diseases, diabetes and cancers, as well as preventing disease outbreaks and reducing their human, economic and social cost by instituting early warning systems and ensuring timely detection and diagnosis of epidemic-prone diseases.

AFCAD aims to address diagnostic gaps holistically. The initiative will share information and compare various investments made across the disease areas. The identification of complementarities, overlaps and gaps will provide clarity about whether end-to-end solutions exist and are being implemented.

Dipo Olowookere is a journalist based in Nigeria that has passion for reporting business news stories. At his leisure time, he watches football and supports 3SC of Ibadan. Mr Olowookere can be reached via [email protected]

Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Health

Chinamanda Ngozi Adichie Blames Medical Negligence for Son’s Death

Published

on

Chimamanda Ngozi Adichie

By Adedapo Adesanya

Renowned Nigerian author, Ms Chinamanda Ngozi Adichie, has alleged that medical negligence was responsible for the death of her 21-month-old child.

The child, Nkanu, reportedly passed away on Wednesday, January 7, 2026, after a brief illness.

More details have emerged detailing the circumstances surrounding his death.

According to a leaked internal message sent privately to family members and close friends, Ms Adichie blamed a staff of Euracare Multi-Specialist Hospital, located in Victoria Island, Lagos, for causing the demise of the lad.

“My son would be alive today if not for an incident at Euracare Hospital on January 6th.

“We were in Lagos for Christmas. Nkanu had what we first thought was just a cold, but soon turned into a very serious infection and he was admitted to Atlantis hospital.

“He was to travel to the US the next day, January 7th, accompanied by Travelling Doctors. A team at Johns Hopkins was waiting to receive him in Baltimore. The Hopkins team had asked for a lumbar puncture test and an MRI. The Nigerian team had also decided to put in a ‘central line’ (used to administer iv medications) in preparation for Nkanu’s flight. Atlantis hospital referred us to Euracare Hospital, which was said to be the best place to have the procedures done.

“The morning of the 6th, we left Atlantis hospital for Euracare, Nkanu carried in his father’s arms. We were told he would need to be sedated to prevent him from moving during the MRI and the ‘central line’ procedure.

“I was waiting just outside the theater. I saw people, including Dr M, rushing into the theater and immediately knew something had happened.

“A short time later, Dr M came out and told me Nkanu had been given too much propofol by the anesthesiologist, had become unresponsive and was quickly resuscitated. But suddenly Nkanu was on a ventilator, he was intubated and placed in the ICU. The next thing I heard was that he had seizures. Cardiac arrest. All these had never happened before. Some hours later, Nkanu was gone

“It turns out that Nkanu was NEVER monitored after being given too much propofol. The anesthesiologist had just casually carried Nkanu on his shoulder to the theater, so nobody knows when exactly Nkanu became unresponsive.

“How can you sedate a sick child and neglect to monitor him? Later, after the ‘central line’ procedure, the anesthesiologist casually switched off Nkanu’s oxygen and again decided to carry him on his shoulder to the ICU!

“The anesthesiologist was CRIMINALLY negligent. He was fatally casual and careless with the precious life of a child. No proper protocol was followed.

“We brought in a child who was unwell but stable and scheduled to travel the next day. We came to conduct basic procedures. And suddenly, our beautiful little boy was gone forever. It is like living your worst nightmare. I will never survive the loss of my child.

“We have now heard about two previous cases of this same anesthesiologist overdosing children. Why did Euracare allow him to keep working? This must never happen to another child,” she wrote.

As of press time, it is not clear what the next line of action will be with the revelation.

Continue Reading

Health

SUNU Health Named Most Customer Focused HMO of the Year

Published

on

SUNU Health --logo

By Modupe Gbadeyanka

The decision of the management of SUNU Health Nigeria Limited to adopt the strategy of placing the enrollee and customer at the heart of its operations has started to pay off.

The company was recently announced as Most Customer-Focused Health Insurance Company of the Year at the Customer Service Standard Magazine Awards 2025.

The recognition underscored the company’s success in translating its dedication into tangible enrollee satisfaction and superior market service at the Nigerian Health Maintenance Organisation (HMO) landscape.

It also highlights the organisation’s dedicated efforts in streamlining claims processing, enhancing access to quality healthcare providers, and maintaining transparent, responsive communication channels with its diverse client base across Nigeria.

The accolade further serves as a powerful testament to the successful integration of digital solutions and human-centric service models at SUNU Health.

It positions the firm as a leader not only in providing robust health plans but also in delivering the supportive, personalized care that enrollees truly value.

“Clinching the Most Customer-Focused Health Insurance Company of the Year award is not just an honour; it is a validation of the core philosophy that drives every member of the SUNU Health team.

“We believe that healthcare is fundamentally a service industry, and our success is measured by the well-being and satisfaction of our enrollees,” the chief executive of SUNU Health, Mr Patrick Korie, commented.

“This award reinforces our resolve to continuously innovate and set new benchmarks for customer experience in the Nigerian health insurance sector.

“Our commitment to providing accessible, high-quality, and seamless healthcare solutions remains our top priority as we move into the new year (2026),” he added.

Continue Reading

Health

Nigeria Launches First National Antimicrobial Resistance Survey

Published

on

Antimicrobial Resistance Survey

By Adedapo Adesanya

Nigeria has launched its first nationally representative survey on antimicrobial resistance to generate critical data to guide evidence-based policies, improve patient outcomes, and strengthen health system resilience.

Antimicrobial resistance occurs when bacteria, viruses, fungi, and parasites evolve to resist treatment, making infections harder to cure.

As a result, surveillance is essential to track resistance patterns, identify priority pathogens, and guide targeted interventions and with support from the World Health Organization (WHO) and other partners, the initiative marks a milestone in the country’s public health response.

Nigeria becomes the third country globally to partner with WHO on a national antimicrobial resistance survey. having been selected based on the country’s strong commitment to AMR surveillance, its updated WHO Nigeria NAP 2.0, and readiness to expand laboratory and data systems.

Africa’s most populous country ranks 20th globally for age-standardized mortality due to antimicrobial resistance . In 2019, an estimated 263,400 deaths in Nigeria were linked to  it—more than the combined deaths from enteric infections, tuberculosis, respiratory infections, maternal and neonatal disorders, neglected tropical diseases, malaria, and cardiovascular diseases.

Globally, resistant infections in tertiary care settings cost between $2,371 and $29,289 per patient episode, extend hospital stays by an average of 7.4 days, and increase mortality risk by 84 per cent.

The survey will see the establishment of a national baseline on antimicrobial resistance prevalence to monitor interventions, assess the distribution, burden (morbidity, mortality, DALYs, cost), and diversity of AMR across regions and populations, as well as contribute to the global target of reducing AMR deaths by 10 per cent by 2030, in line with the political declaration endorsed at the 79th United Nations General Assembly in 2024.

It also seeks to strengthen routine antimicrobial resistance surveillance, including diagnostics, sample referral systems, and laboratory capacity.

Using WHO’s standardized methodology, the survey will run for 12–15 months and cover 40–45 randomly selected health facilities nationwide. Patients with suspected bloodstream infections (BSIs) will be identified using standard case definitions, and blood samples will be analysed in quality-assured laboratories.

Data will be collected across all age groups, covering clinical, demographic, laboratory, financial, and outcome indicators. Follow-up will occur at discharge, 28 days, and three months post-infection. The survey will sample approximately 35,000 patients suspected of BSIs to obtain around 800 isolates of the most common pathogens.

Dr Tochi Okwor, Acting Head, Disease Prevention and Health Promotion, Nigeria Centre for Disease Control and Prevention (NCDC) said, “With WHO’s support, we are confident the survey will generate the evidence needed to protect public health.”

WHO Representative in Nigeria, Dr Pavel Ursu, reaffirmed WHO’s commitment stating that ,“Nigeria is taking a decisive step toward combating AMR with an approach grounded in data, science, and measurable impact. This survey will provide the clarity needed to drive smarter policies, stronger surveillance, and better patient outcomes. Nigeria is laying the foundations for a resilient health system, one that protects lives, strengthens trust, and ensures that essential medicines remain effective for future generations.”

Adding her input, Dr Laetitia Gahimbare, Technical Officer at WHO Regional Office for Africa, added:“Strengthening surveillance enhances Nigeria’s capacity to detect and respond to AMR threats, supporting better patient outcomes, reinforcing health security, and building a resilient system.”

Professor Babatunde Ogunbosi, Paediatric Infectious Diseases Specialist at University College Hospital, Ibadan, highlighted the broader impact:, “This survey is about more than data. It’s about building national capacity for research, diagnostics, and policy. It integrates science into public health decision-making.”

Continue Reading

Trending